Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study

Woo

J of Gastro and Hepatol

et al. 2017

Section: Methodsmentioning

confidence: 99%

“…The dose was selected based on the findings of previous clinical studies. 15,23 During the study period, patients were prohibited from taking laxatives, rescue medications for constipation, or other GI motility regulators.…”

Section: Methodsmentioning

confidence: 99%

DA‐9701 improves colonic transit time and symptoms in patients with functional constipation: A prospective study

Woo

J of Gastro and Hepatol

et al. 2017

“…104,105 PPIs are the most effective medicines for treating GERD. 106 Therefore, patients with GERD are frequently treated with PPIs.…”

Section: Sex/gender and Treatment Responsementioning

confidence: 99%

Sex and Gender Differences in Gastroesophageal Reflux Disease

J Neurogastroenterol Motil

2016

128

It is important to understand sex and gender-related differences in gastroesophageal reflux disease (GERD) because gender-related biologic factors might lead to better prevention and therapy. Non-erosive reflux disease (NERD) affects more women than men. GERD symptoms are more frequent in patients with NERD than in those with reflux esophagitis. However, men suffer pathologic diseases such as reflux esophagitis, Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC) more frequently than women. The prevalence of reflux esophagitis is significantly increased with age in women, especially after their 50s. The mean age of EAC incidence in women is higher than in men, suggesting a role of estrogen in delaying the onset of BE and EAC. In a chronic rat reflux esophagitis model, nitric oxide was found to be an aggravating factor of esophageal injury in a male-predominant way. In addition, the expression of esophageal occludin, a tight junction protein that plays an important role in the esophageal defense mechanism, was up-regulated in women. This explains the male predominance of reflux esophagitis and delayed incidence of BE or EAC in women. Moreover, the symptoms such as heartburn, regurgitation, and extra-esophageal symptoms have been more frequently reported by women than by men, suggesting that sex and gender play a role in symptom perception. Differential sensitivity with augmented symptoms in women might have diagnostic and therapeutic influence. Furthermore, recent studies have suggested that hormone replacement therapy has a protective effect against esophageal cancer. However, an anti-inflammatory role of estrogen remains compelling, which means further study is necessary in this area.

“…A randomized, double-blind, placebo-controlled study for the effect of DA-9701 on GERD was conducted in 81 patients with minimal change esophagitis presenting with reflux and dyspeptic symptoms (134). Although the Nepean dyspepsia index and QoL were improved after 4 weeks, 30 mg DA-9701 three times a day was not superior to placebo.…”

Section: Gastroesophageal Reflux Disordermentioning

confidence: 99%

Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication

Na-yeon

et al. 2020

Front. Psychiatry

The pathophysiology of functional gastrointestinal disorders (FGIDs) is still unclear and various complex mechanisms have been suggested to be involved. In many cases, improvement of symptoms and quality of life (QoL) in patients with FGIDs is difficult to achieve with the single-targeted treatments alone and clinical application of these treatments can be challenging owing to the side effects. Herbal preparations as complementary and alternative medicine can control multiple treatment targets of FGIDs simultaneously and relatively safely. To date, many herbal ingredients and combination preparations have been proposed across different countries and together with a variety of traditional medicine. Among the herbal therapies that are comparatively considered to have an evidence base are iberogast (STW-5) and peppermint oil, which have been mainly studied and used in Europe, and rikkunshito and motilitone (DA-9701), which are extracted from natural substances in traditional medicine, are the focus of this review. These herbal medications have multi-target pharmacology similar to the etiology of FGIDs, such as altered intestinal sensory and motor function, inflammation, neurohormonal abnormality, and have displayed comparable efficacy and safety in controlled trials. To achieve the treatment goal of refractory FGIDs, extensive and high quality studies on the pharmacological mechanisms and clinical effects of these herbal medications as well as efforts to develop new promising herbal compounds are required.